JP2005536220A - 腫瘍関連抗原ｍｎ／ｃａｉｘの発現に特徴付けられる癌のための治療組成物ならびに治療方法 - Google Patents

腫瘍関連抗原ｍｎ／ｃａｉｘの発現に特徴付けられる癌のための治療組成物ならびに治療方法 Download PDF

Info

Publication number
JP2005536220A
JP2005536220A JP2004531195A JP2004531195A JP2005536220A JP 2005536220 A JP2005536220 A JP 2005536220A JP 2004531195 A JP2004531195 A JP 2004531195A JP 2004531195 A JP2004531195 A JP 2004531195A JP 2005536220 A JP2005536220 A JP 2005536220A
Authority
JP
Japan
Prior art keywords
carbonic anhydrase
antibody
residues
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004531195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536220A5 (https=
Inventor
ジャスティン ウォン，
ジル ウィンター，
グイタ ラレーザデ，
ロバート ワーン，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JP2005536220A publication Critical patent/JP2005536220A/ja
Publication of JP2005536220A5 publication Critical patent/JP2005536220A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004531195A 2002-08-23 2003-08-25 腫瘍関連抗原ｍｎ／ｃａｉｘの発現に特徴付けられる癌のための治療組成物ならびに治療方法 Withdrawn JP2005536220A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40557702P 2002-08-23 2002-08-23
US64693403A 2003-08-22 2003-08-22
PCT/US2003/026612 WO2004017923A2 (en) 2002-08-23 2003-08-25 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix

Publications (2)

Publication Number Publication Date
JP2005536220A true JP2005536220A (ja) 2005-12-02
JP2005536220A5 JP2005536220A5 (https=) 2006-09-14

Family

ID=31949897

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004531195A Withdrawn JP2005536220A (ja) 2002-08-23 2003-08-25 腫瘍関連抗原ｍｎ／ｃａｉｘの発現に特徴付けられる癌のための治療組成物ならびに治療方法

Country Status (5)

Country Link
EP (1) EP1576010A4 (https=)
JP (1) JP2005536220A (https=)
AU (1) AU2003268180A1 (https=)
CA (1) CA2496572A1 (https=)
WO (1) WO2004017923A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519341A (ja) * 2005-12-12 2009-05-14 バイエル・ヘルスケア・エルエルシー 抗ｍ抗体およびそれらを使用する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3031910T3 (en) 2002-02-21 2017-10-23 Inst Virology MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE
US7833734B2 (en) 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
WO2008091798A2 (en) * 2007-01-22 2008-07-31 Xencor, Inc. Optimized ca9 antibodies and methods of using the same
JP2011517313A (ja) * 2007-12-11 2011-06-02 ビアメト ファーマシューティカルズ，インク． 金属結合部分を標的化部分と組み合わせて使用する金属酵素阻害剤
WO2020226612A1 (en) * 2019-05-06 2020-11-12 Navi Bio-Therapeutics, Llc Anti-carbonic anhydrase ix antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955075A (en) * 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
JP3910798B2 (ja) * 1998-10-23 2007-04-25 インスティトゥート オブ ヴァイロロジー Ｍｎ遺伝子およびタンパク質

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009519341A (ja) * 2005-12-12 2009-05-14 バイエル・ヘルスケア・エルエルシー 抗ｍ抗体およびそれらを使用する方法
JP2012211153A (ja) * 2005-12-12 2012-11-01 Bayer Healthcare Llc 抗ｍ抗体およびそれらを使用する方法

Also Published As

Publication number Publication date
CA2496572A1 (en) 2004-03-04
EP1576010A4 (en) 2006-12-27
WO2004017923A3 (en) 2005-07-14
WO2004017923A2 (en) 2004-03-04
AU2003268180A8 (en) 2004-03-11
EP1576010A2 (en) 2005-09-21
AU2003268180A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
RU2549684C2 (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP5897300B2 (ja) 腫瘍治療のための組成物と方法
CN107250160B (zh) 人源化cc趋化因子受体4 (ccr4)抗体及其使用方法
US20060062727A1 (en) Compositions and methods for the diagnosis and treatment of tumor
CA2988115A1 (en) Anti-gitr antibodies for cancer diagnostics
JP2009531031A (ja) 抗−腫瘍細胞抗原抗体療法
KR20150008095A (ko) 암 진단에 유용한 클로딘 18.2에 대한 항체
JP2004520806A (ja) 腫瘍の診断と治療のための組成物と方法
EP2295073B1 (en) Antibody against CD22 for the treatment of tumour of hematopoietic origin
EP2217625A2 (en) Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
US20080241126A1 (en) Nucleic acids encoding Human Engineered heavy and light chain variable region sequences to Ep-CAM
KR101410195B1 (ko) 헵신을 표적화하기 위한 방법 및 조성물
JP2005531491A (ja) 癌の治療のための組成物と方法
JP2004520810A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007521791A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006519774A (ja) 癌の治療のための組成物と方法
US20090252738A1 (en) Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
JP2005536220A (ja) 腫瘍関連抗原ｍｎ／ｃａｉｘの発現に特徴付けられる癌のための治療組成物ならびに治療方法
CA2422538C (en) Notch receptor agonists and uses
US12139551B2 (en) Anti-IDO antibody and uses thereof
US20080241066A1 (en) Anti-PRL-3 antibodies and methods of use thereof
US20040258696A1 (en) Compositions and methods for the diagnosis and treatment of tumor
JP2006512901A (ja) Ａｃｈａｅｔｅ−Ｓｃｕｔｅ様−２ポリペプチドとそのコード化核酸並びに腫瘍の診断と治療のための方法
JP2004520808A (ja) 腫瘍の診断と治療のための組成物と方法
CN121358780A (zh) 与lilrb1结合的抗体或抗原结合片段及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090730

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090831

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090907

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090928

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091005

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20091028